SNDL Inc.
HealthcareNASDAQ:SNDL · NASDAQ Capital Market
-$0.04 today
Vol 2.20M · Avg 2.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1.4%
avg -42.9%
ROIC
-0.3%
avg -22.5%
ROA
-1.2%
avg -28.0%
Analysis
ROIC is currently the strongest return metric at -0.3% versus its period average of -22.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Zachary Ryan George | Chief Executive Officer & Non Independent Director | $1.93M | — | 48 | — | — |
Alberto Paredero-Quiros | Chief Financial Officer | $947,119.00 | — | 52 | — | — |
Ryan Hellard | Chief Strategy Officer & Interim President of Cannabis | $301,155.00 | — | 37 | — | — |
Matthew Scott Husson | General Counsel & Corporate Secretary | $260,589.00 | — | 44 | — | — |
Phil McBride | Chief Information Officer | — | — | 51 | — | — |
Deanna Garand | Vice President of Human Resources | — | — | 43 | — | — |
Navroop Sandhawalia | President of Liquor Division | — | — | 38 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +79.8% | +39.3% (9yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +79.8% over three years. Forward estimates point to Revenue at +39.3% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
Emergent BioSolutions Inc.
NYSE:EBS
$429.28M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Who manages SNDL?
SNDL Inc. (SNDL) lists 7 active executives. The top listed executive is Phil McBride, Chief Information Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.